AptaTeck Bio

Company Overview

Snapshot

Founded in January 2009 by Ofer Nussbaum, AptaTeck Bio operates with 1–10 employees. The company focuses on immuno-diagnostic assays and ceased operations in January 2015.

Business overview

AptaTeck Bio develops highly sensitive immuno-diagnostic assays based on a proprietary amplification probe technology. This technology utilizes both antibodies and aptamers to generate specific, accurate, and reproducible immune diagnostics. The system is compatible with various automated and manual platforms, including ELISA assays and flow cytometry, and is designed for cost-effective, accurate diagnosis at the point of care. AptaTeck Bio's technology is suitable for detecting a range of target molecules, including biomarkers, viral and bacterial antigens, nucleic acids, and cell surface and soluble antigens within the Pharmaceuticals sector.

Company Intelligence Q&A

What is AptaTeck Bio's primary focus?

AptaTeck Bio focuses on developing highly sensitive immuno-diagnostic assays using a proprietary amplification probe technology.

When was AptaTeck Bio founded?

AptaTeck Bio was founded in January 2009.

Who is a founder of AptaTeck Bio?

Ofer Nussbaum is a co-founder and CTO of AptaTeck Bio.

What is the status of AptaTeck Bio?

AptaTeck Bio is non-active and ceased to operate in January 2015.

Where is AptaTeck Bio headquartered?

AptaTeck Bio is headquartered in Jerusalem, Israel.